Apogee Therapeutics Inc (APGE)

Mar 3, 2025, 12:16 PM EST - 4 weeks ago

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Mar 3, 2025, 6:05 AM EST - 4 weeks ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Mar 3, 2025, 6:00 AM EST - 4 weeks ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Feb 28, 2025, 4:00 PM EST - 4 weeks ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Feb 25, 2025, 7:30 AM EST - 5 weeks ago

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Feb 3, 2025, 7:00 AM EST - 2 months ago

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Jan 29, 2025, 7:30 AM EST - 2 months ago

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Dec 2, 2024, 6:00 AM EST - 4 months ago

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Nov 29, 2024, 1:00 PM EST - 4 months ago

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Nov 18, 2024, 7:30 AM EST - 4 months ago

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Nov 10, 2024, 9:55 AM EST - 5 months ago

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Nov 4, 2024, 7:30 AM EST - 5 months ago

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 6 months ago

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

Sep 12, 2024, 7:00 AM EDT - 7 months ago

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

Sep 9, 2024, 7:00 AM EDT - 7 months ago

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

Aug 19, 2024, 7:00 AM EDT - 8 months ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Aug 12, 2024, 6:30 AM EDT - 8 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Jun 18, 2024, 10:05 AM EDT - 10 months ago

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

May 28, 2024, 7:30 AM EDT - 11 months ago

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

May 23, 2024, 7:30 AM EDT - 11 months ago

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

May 15, 2024, 4:01 PM EDT - 11 months ago

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

May 13, 2024, 7:00 AM EDT - 11 months ago

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

May 6, 2024, 8:00 AM EDT - 11 months ago

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Mar 12, 2024, 4:01 PM EDT - 1 year ago

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million

Mar 7, 2024, 6:49 PM EST - 1 year ago

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

Mar 6, 2024, 4:13 PM EST - 1 year ago

Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 Advancement

Mar 5, 2024, 4:23 PM EST - 1 year ago

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Mar 5, 2024, 1:28 PM EST - 1 year ago

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management

Mar 5, 2024, 6:10 AM EST - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 6:00 AM EST - 1 year ago

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc

Mar 4, 2024, 4:01 PM EST - 1 year ago

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

Jan 2, 2024, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 7:30 AM EST - 1 year ago

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Sep 27, 2023, 8:42 AM EDT - 1 year ago

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

Sep 14, 2023, 7:30 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day

Aug 29, 2023, 8:00 AM EDT - 1 year ago

Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics

Aug 28, 2023, 7:30 AM EDT - 1 year ago

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 8:14 AM EDT - 1 year ago

Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing

Aug 21, 2023, 7:30 AM EDT - 1 year ago

Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board

Aug 7, 2023, 7:30 AM EDT - 1 year ago

Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Aug 2, 2023, 7:30 AM EDT - 1 year ago

Apogee Therapeutics to Participate in Upcoming August Investor Conferences

Jul 18, 2023, 4:01 PM EDT - 1 year ago

Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jul 15, 2023, 3:28 AM EDT - 1 year ago

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs

ODD OPHV SGMT SRFM TURB

Jul 13, 2023, 6:32 PM EDT - 1 year ago

Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering

Jul 10, 2023, 5:33 PM EDT - 1 year ago

IPO Update: Apogee Therapeutics Proposes Terms For $250 Million IPO

Jul 10, 2023, 6:28 AM EDT - 1 year ago

Apogee Therapeutics sets IPO terms, to be valued at up to $774.5 mln

Jul 8, 2023, 4:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Nano-Cap Debuts In Short And Quiet Holiday Week

ODD

Jun 26, 2023, 1:30 PM EDT - 1 year ago

Apogee Therapeutics Begins $100 Million IPO Rollout